A prospective, longitudinal, multicenter to determine real-world outcomes for safety and effectiveness of Eculizumab and switch to Ravulizumab using data from Swiss Soliris and Ultomiris Reimbursement Registry (SSURR)
Latest Information Update: 14 Aug 2022
At a glance
- Drugs Eculizumab (Primary) ; Ravulizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 14 Aug 2022 New trial record
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association